The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Fred Saad,Kim N Chi,Antonio Finelli,Sebastien J Hotte,Jonathan Izawa,Anil Kapoor,Wassim Kassouf,Andrew Loblaw,Scott North,Ricardo Rendon,Alan So,Nawaid Usmani,Eric Vigneault,Neil E Fleshner

Canadian Urological Association journal = Journal de l'Association des urologues du Canada（2015）

引用 0|浏览12

暂无评分

摘要

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要